Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 158-161

  Adler, Charles H ^a   Factor, Stewart A ^b   Brin, Mitchell ^c   Sethi, Kapil D ^d  

^a MAYO CLINIC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Botulinum toxin; Immunoresistance; Oromandibular dystonia

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSTONIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; JAW MOVEMENT; MALE; MANDIBLE RECONSTRUCTION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TEMPOROMANDIBULAR JOINT DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; TRISMUS; WESTERN BLOTTING;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DRUG RESISTANCE; DYSTONIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MANDIBULAR DISEASES; MIDDLE AGED; NEUROMUSCULAR AGENTS;

EID: 0036461016     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10001     Document Type: Article

References (13)

1. Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 1994;7:358-366.
2. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37:616-623.
3. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93-97.
4. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107.
5. Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994;44:70-76.
6. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-29.
7. Smith ME, Ford CN. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000; 126:533-535.
8. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213- 217.
9. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
10. Greene P, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
11. Sheean GL, Lees AJ. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;59:601-607.
12. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
13. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999;66:612-616.